Harvard Bio Posts 12-Percent Revenue Gain in Q2, Ups '06 Guidance | GenomeWeb
NEW YORK (GenomeWeb News) – Harvard Bioscience today reported that improved sales in the second quarter helped recude net loss by more than 98 percent.
 
Receipts for the three months ended June 30 increased 12 percent to $18 million from $16 million year over year as a result of improved product mix and higher margins on new product introductions, Harvard Bio said.
 
R&D costs increased 10 percent to $773,000 from $704,000 from the comparable quarter a year ago.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.